Modern treatment approaches offer numerous options ... Acupuncture shows promise in reducing overactive bladder symptoms and stress incontinence. However, results vary among individuals, and more ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

One explanation for this is our inability to differentiate between symptoms attributable to detrusor overactivity (DO) and those caused by bladder ... to tamsulosin treatment comprises men with ...

Imbrium Therapeutics L.P. ("Imbrium"), a subsidiary of Purdue Pharma L.P. ("Purdue"), announced results from a Phase 1b clinical signal detection study evaluating the safety and efficacy of the novel ...

This is called an Overactive Bladder ( OAB ... assess both the storage and voiding phases of the urinary bladder. What are the treatment options available ? The conservative strategies to ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Urination problems affect millions of men worldwide, often developing so gradually that many dismiss early warning signs.

An overactive bladder may be temporary or become a chronic condition. How long the symptoms last may depend on factors like the underlying cause and treatment adherence. Some conditions may cause ...

An important question is how PTNS compares with the established alternatives for the treatment of overactive bladder. Established treatments would include non-pharmacologic measures such as ...